Streetbeat News

Products Services

EOLS

Evolus has announced the results from its Phase 2 clinical study evaluating the 'extra-strength' 40U dose for extended duration of Jeuveau. The 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment. The results indicate a similar safety profile to lower dose arms in the study.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:49 pm

BAK

Brazilian petrochemical companies Braskem and Indorama Ventures IOD - Oxiteno have announced a partnership to supply bio-attributed ethylene from renewable sources. The raw material, certified by ISCC, will be used by Oxiteno to create new sustainable solutions. This is the first bio-attributed chemical product produced by Braskem from the certified mass balance approach, which co-processes traditional carbon sources with recycled or renewable components.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:49 pm

AKTX

Akari Therapeutics, Plc (NASDAQ:AKTX) announced that its Chief Scientific Officer will present a poster on the development of PASylated®-Nomacopan for Treatment of Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development conference. The long-acting PAS-nomacopan is in the final stages of pre-clinical development as a potential treatment for GA.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:49 pm

HRT

HireRight Holdings Corporation (NYSE:HRT) has launched an operational entity in Brazil, marking a significant milestone in its regional expansion strategy. This move aims to enhance support for customers hiring in Brazil and throughout Latin America. The expansion follows the launch of HireRight's Mexico subsidiary in 2021 and the acquisition of Inquiro Vitae in Argentina earlier this year. With this expansion, HireRight aims to provide faster data to customers screening in Brazil through direct connections to local sources and offer local fulfilment of verifications and customer support in Portuguese.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:48 pm

INAB

IN8bio, Inc. (NASDAQ:INAB) presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme (GBM) at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data demonstrated the ability of INB-200, a DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response. The company will present updated patient, survival and enrollment data from the study at the Society for Neuro-Oncology (SNO) Annual Meeting on November 17, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:47 pm

TKLF

Yoshitsu Co., Ltd (NASDAQ:TKLF), a retailer and wholesaler of Japanese beauty and health products, has established a wholly-owned Canadian subsidiary, RAKKISTAR HOLDING INC. The new subsidiary is expected to enhance Yoshitsu's service standards in the North American market, strengthen customer relationships, and increase sales. The direct-sale model is expected to bring the company closer to its customers and optimize its management structure.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:46 pm

CBUS

Cibus, Inc. (NASDAQ:CBUS), an agricultural technology company, has acknowledged the European Parliament's draft report on the proposal for regulation of plants obtained from New Genomic Techniques (NGTs). The proposal supports the introduction of a new regulation on plants obtained by NGTs and identifies a 'Conventional-like' category of NGT products. This would bring EU policy closer to that of trading partners in North and South America, Australia, and Japan. Products from Cibus' gene editing platform, such as disease-resistant canola and oilseed rape, would be considered 'Conventional-like'.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:45 pm

SLNO

Soleno Therapeutics (NASDAQ:SLNO) has published one-year results from the Phase 3 DESTINY PWS study and the open-label extension period of Study C602, evaluating DCCR (Diazoxide Choline) Extended-Release tablets for patients with Prader-Willi syndrome (PWS). The study demonstrated significant, sustained reductions in hyperphagia, a chronic feeling of insatiable hunger that severely diminishes the quality of life for PWS patients. Soleno anticipates submitting an NDA to the FDA for DCCR in mid-2024.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:44 pm

MBRX

Moleculin Biotech, Inc. (NASDAQ:MBRX) has presented preliminary efficacy findings from its Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma lung metastases. The trial demonstrated a 64% stable disease rate through two cycles of Annamycin. The drug continues to be 100% non-cardiotoxic and has Fast Track Status and Orphan Drug Designation from the FDA. The company's CEO, Walter Klemp, expressed confidence in the potential of Annamycin to be a meaningful treatment option for patients.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:44 pm

NRGV

Energy Vault Holdings, Inc. (NYSE:NRGV) has announced five new deployments of its EVx gravity energy storage systems in China, bringing the total planned deployments in the country to seven. The projects, which are being deployed by China Tianying Inc. (CNTY), are expected to total 3.26 GWh and have a project scope of over $1 billion. Energy Vault collects a 5% revenue royalty from these projects. The first EVx system is under final commissioning in Rudong and will be the world's first commercial, grid-scale gravity energy storage system.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:42 pm